Felzartamab vs Lumrotatug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Felzartamab
Developed by Biogen and partners
NCT03952091 · Phase 3 · completed
This was a large (n=289), randomized, active-controlled Phase 3 trial using a well-accepted hard clinical endpoint (progression-free survival), and the drug combination showed a statistically significant improvement over the active comparator. However, the trial was conducted completely open-label with no blinding of patients or investigators, which limits confidence in the result despite its objective endpoint and statistical significance.
Reported efficacy
Progression-free survival (PFS) (18.4 months(Active) 30.7 months(experimental)): Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035) (met)
Result source: NCT03952091
Lumrotatug
Developed by Timberlyne Therapeutics and partners
NCT04818372 · Phase 1 · status unknown
This is an early, single-arm, open-label safety and dose-finding study with no randomization or comparator group, so it cannot show whether CM313 works better than another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: May 2030 · NCT07910903 (registry estimate)
Reported efficacy
Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT) (Up to 21 days after the first dose); Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 (Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier); Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patients (Up to 24 months): CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
Result source: NCT04818372
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Felzartamab | Lumrotatug |
|---|---|---|
| PFS, median | —Not posted · NCT03952091 | —Trial running · NCT07910903 |
| OS, median | —Not posted · NCT03952091 | —Trial running · NCT07910903 |
| ORR | —Not posted · NCT03952091 | —Trial running · NCT07910903 |
| VGPR or better | —Not posted · NCT03952091 | —Trial running · NCT07910903 |
| MRD negativity | —Not posted · NCT03952091 | —Trial running · NCT07910903 |
PFS, median
- Felzartamab
- —Not posted · NCT03952091
- Lumrotatug
- —Trial running · NCT07910903
OS, median
- Felzartamab
- —Not posted · NCT03952091
- Lumrotatug
- —Trial running · NCT07910903
ORR
- Felzartamab
- —Not posted · NCT03952091
- Lumrotatug
- —Trial running · NCT07910903
VGPR or better
- Felzartamab
- —Not posted · NCT03952091
- Lumrotatug
- —Trial running · NCT07910903
MRD negativity
- Felzartamab
- —Not posted · NCT03952091
- Lumrotatug
- —Trial running · NCT07910903
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Felzartamab's landscape · Lumrotatug's landscape